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Abstract
Background: New drugs are needed to treat visceral leishmaniasis (VL) because the current therapies are toxic, expensive,
and parasite resistance may weaken drug efficacy. We established a novel ex vivo splenic explant culture system from
hamsters infected with luciferase-transfected Leishmania donovani to screen chemical compounds for anti-leishmanial
activity.
Methodology/Principal Findings: This model has advantages over in vitro systems in that it: 1) includes the whole cellular
population involved in the host-parasite interaction; 2) is initiated at a stage of infection when the immunosuppressive
mechanisms that lead to progressive VL are evident; 3) involves the intracellular form of Leishmania; 4) supports parasite
replication that can be easily quantified by detection of parasite-expressed luciferase; 5) is adaptable to a high-throughput
screening format; and 6) can be used to identify compounds that have both direct and indirect anti-parasitic activity. The
assay showed excellent discrimination between positive (amphotericin B) and negative (vehicle) controls with a Z’ Factor
.0.8. A duplicate screen of 4 chemical libraries containing 4,035 compounds identified 202 hits (5.0%) with a Z score of ,
–1.96 (p,0.05). Eighty-four (2.1%) of the hits were classified as lead compounds based on the in vitro therapeutic index
(ratio of the compound concentration causing 50% cytotoxicity in the HepG2 cell line to the concentration that caused 50%
reduction in the parasite load). Sixty-nine (82%) of the lead compounds were previously unknown to have anti-leishmanial
activity. The most frequently identified lead compounds were classified as quinoline-containing compounds (14%), alkaloids
(10%), aromatics (11%), terpenes (8%), phenothiazines (7%) and furans (5%).
Conclusions/Significance: The ex vivo splenic explant model provides a powerful approach to identify new compounds
active against L. donovani within the pathophysiologic environment of the infected spleen. Further in vivo evaluation and
chemical optimization of these lead compounds may generate new candidates for preclinical studies of treatment for VL.
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Introduction
New drugs are desperately needed to treat visceral leishmaniasis
(VL), and this in turn requires new approaches to discover novel
lead compounds that might populate a pipeline of new
therapeutics for patients with VL. Current therapies for the
leishmaniases are toxic, difficult to deliver, expensive, and their
efficacy is hindered by parasite resistance (reviewed in [1]). The
pentavalent antimony compounds, sodium stibogluconate and
meglumine antimoniate, have been the mainstay of anti-
leishmanial chemotherapy for more than 40 years. The recom-
mended regimen involves prolonged and often repeated courses of
drug administered by the intravenous or intramuscular routes.
Cure rates of 80–100% were common in the 1990s, but have
dropped off considerably because of parasite resistance [2].
Adverse effects of antimony therapy are multiple and often dose-
limiting. Amphotericin B desoxycholate and the amphotericin
lipid formulations are also used in the treatment of VL, and in
many regions have replaced antimony as first-line therapy. The
use of these drugs, however, is limited by their difficulty of
administration, well-known risk of toxicity, and high cost.
Parenteral treatment of VL with the aminoglycoside paromomycin
(aminosidine) is used in India but not licensed in the U.S.
Miltefosine, a membrane targeting alkylphospholipid, was recently
licensed in India as the first oral treatment for VL, but after only a
few years of use, drug resistance has emerged. The discovery of
www.plosntds.org 1 February 2011 | Volume 5 | Issue 2 | e962new drugs for VL would have huge impact on individual patients
and on populations in the endemic area as a whole.
Pre-clinical in vitro studies to identify candidate drugs for
treatment of leishmaniasis have employed several different
approaches, each of which has significant limitations. The testing
of drugs using axenically cultured parasites, usually promastigotes,
has been most commonly used, but this approach is limited by 1)
the discordance of anti-leishmanial activity of compounds tested in
axenically cultured promastigotes (vector stage) and amastigotes
(mammalian stage) [3,4], and 2) the testing of antiparasitic activity
in the absence of host immune cells, which are known to
profoundly influence parasite replication or killing [5,6,7,8]. The
use of cultured macrophages that have been infected in vitro with
Leishmania has the advantage of identifying drugs that are active
against the intracellular amastigote, but in vitro infections are
technically cumbersome, may have a variable number of
promastigotes that remain attached but not internalized by
macrophages, and the isolated macrophage-amastigote infection
excludes other immunomodulatory host cells such as disease
promoting or regulatory T cells (reviewed in [9]).
Pre-clinical in vivo studies have largely used murine models of
Leishmania infection, however, L. donovani infection in mice does not
fully represent the features of active VL, and thus arrest or cure of
severe, progressive disease and death cannot be an endpoint in
therapeutic trials in mice. Strikingly, Syrian hamsters recapi-
tulate the progressive clinicopathological features of human VL
[10,11,12], most notably the profound immunosuppression
associated with active disease that has fundamental importance
to effective therapy. During progressive disease in the hamster
model of VL, a Type 1 T cell response is mounted, but
paradoxically it is ineffective [11,12]. This contrasts sharply with
the mouse model, but is very similar to what has been
demonstrated in humans with VL [13,14], who also mount an
ineffective Type 1 response. Most notably, progressive disease in
hamsters is accompanied by low NOS2 expression [11], and
infected hamster macrophages, akin to human macrophages
[15,16] produce very low levels of NO [17]. In striking contrast,
activated mouse macrophages produce high levels of NO.
Thus, the macrophage defense against intracellular pathogens in
hamsters is uniquely similar to what is observed in human
macrophages.
Because of the profound influence of the host immune response
on the treatment of Leishmania infection we sought to develop a test
system that included the immunopathological milieu found at the
site of the host-parasite interaction and active disease. This would
enable the activity of new compounds to be determined within
the context of the pathogenic mechanisms that contribute to
progressive disease. To accomplish this, an ex vivo explant culture
of spleen cells from L. donovani infected hamsters was established
from hamster spleens at a point in the course of infection (day 21
post-infection) when disease and parasite replication are dramat-
ically increased. This transition to explosive parasite replication
and progressive disease is accompanied by a loss of T cell
responsiveness (as occurs in human disease) and the development
of an alternatively activated macrophage phenotype. The use of a
parasite strain that expressed luciferase enabled determination of
parasite killing by a large number of compounds in a medium- to
high-throughput format. This approach enabled the identification
anti-leishmanial drug candidates that are active in the face of
the disease-promoting immune response, as must occur in the
treatment of human VL.
Materials and Methods
Animals and parasites
Female inbred Chester Beatty hamsters (6–8 weeks-old) derived
from our own breeding colony were used. Leishmania donovani
(MHOM/SD/001S-2D) promastigotes were cultured in complete
M199 (0.12 mM adenine, 0.0005% Hemin, 20% FBS) as
described previously [18]. The L. donovani strain was transfected
with an episomal vector containing the luciferase (luc) reporter
gene [19] and was maintained routinely by isolation from infected
hamsters, selection in complete M199 with 10 mg/ml of G418,
and intracardial subinoculation of new hamsters approximately
every 3 months. These studies were reviewed and approved by the
Institutional Animal Care and Use Committee of the University of
Texas Health Science Center.
Development of the ex vivo splenic explant culture
Groups of 8 animals were infected by the intracardial route with
10
6 purified metacyclic promastigotes [11] and the body and
spleen weights recorded at 7, 14 and 21 days post-infection. At
each time point, the splenocytes were harvested as described below
and the number of cells and parasite burden determined by
microscopy and luminometry, respectively. The luminometry
counts were transformed to number of parasites using a linear
standard curve of luciferase activity versus number of microscop-
ically enumerated amastigotes. The amastigotes used for the
standard curve were isolated from a cell suspension from hamster
spleen at 20–30 days p.i. as follows: A splenocyte suspension was
obtained by passing the spleen through a wire mesh and then the
splenocytes were disrupted by passing sequentially through 27GK
and 30GK needles, and polycarbonate membrane filters having
pore sizes of 8 mm, 5 mm and 3 mm (Isopore, Millipore). Released
amastigotes (free of host cells) were washed twice with PBS (3000 g
610 min) and enumerated by direct microscopy. The alternative
activation of macrophages was assessed by determining the
arginase activity by the rate of urea formation from L-arginine
in the presence of 1-phenyl-1,2-propanedione-2-oxime (ISPF) [20]
and measuring the soluble collagen content (Sircol Assay, Biocolor
Ltd). The cellular immune response was evaluated by the
proliferative response of spleen cells to Concanavalin A as
described [21].
Author Summary
Visceral leishmaniasis is a life threatening parasitic disease
present in several countries of the world. New drugs are
needed to treat this disease because treatments are
becoming increasingly ineffective. We established a novel
system to screen for new anti-leishmanial compounds that
utilizes spleen cells from hamsters infected with the
parasite Leishmania donovani. The parasite strain we used
was genetically engineered to emit light by the incorpo-
ration of the firefly luciferase gen. This laboratory test
system has the advantage of reproducing the cellular
environment where the drug has to combat the infection.
The efficacy of the compounds is easily determined by
measuring the light emitted by the surviving parasites in a
luminometer after exposing the infected cells to the test
compounds. The screening of more than 4,000 molecules
showed that 84 (2.1%) of them showed anti-leishmanial
activity and had an acceptable toxicity evaluation. Eighty
two percent of these molecules, which had varied
chemical structures, were previously unknown to have
anti-leishmanial activity. Further studies in animals of these
new chemical entities may identify drug candidates for the
treatment of visceral leishmaniasis.
Screening of Anti-Leishmanial Compounds
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The general cell composition of the spleen explant was
determined by microscopy and flow cytometry at 7, 14 and 21
days post-infection and compared with uninfected spleen cells.
The spleen cells were suspended in DMEM +5% FBS at 10
6 cells/
100 ml, washed with PBS plus 0.1% BSA and 0.025% sodium
azide, blocked for 20 min with PBS with 2% BSA and 5% of
normal serum of the species in which the secondary antibodies
were raised, and labeled with the monoclonal antibodies that are
known to cross react with the corresponding hamster molecules.
CD4 T cells were quantified by staining with rat anti-mouse CD4-
PE (clone GK1.5; BD, 0.5 mg/tube) [22] followed by fixation,
permeabilization (Leucoperm; Serotec), and labeling with rat anti-
human CD3-FITC (CD3-12, Serotec, 0.5 mg per tube) which
recognizes a highly conserved intracellular epitope of the CD3
molecule expressed by T lymphocytes in several species (manu-
facturer’s data). B lymphocytes were quantified by labeling cells
that expressed both the MHCII alloantigen (mouse anti-mouse
I-E[k]-PE [clone 14-4-4S], BD, 0.5 mg/tube) [23] and IgG (Goat
F(ab’)2 anti-hamster IgG (clone Dlight 488; Serotec, 1 mg per
tube). In all cases the percent of positive cells was determined by
flow cytometry (FacsAria, BD) according to the threshold of the
corresponding isotype controls.
Parasite replication in the ex vivo spleen explant culture
The number of parasites and the proportion of infected
macrophages were determined after 0, 24, 48 and 72 hours of
ex vivo culture at 37uC, 5% C02 using luminometry and light
microscopy. The ability of the luminometric assay to discriminate
between treated and untreated (control) splenic explant cultures
was assessed in serial two-fold dilutions of cells cultured for 48 h in
100 ml of 0.2 mM amphotericin B (Sigma) or vehicle control.
Splenic explant culture for drug screening and EC50
determinations
To establish the plate assay for drug screening, the spleens from
2 infected hamsters were aseptically removed and placed in a Petri
dish containing 5 mL of Collagenase D (Roche) at 2 mg/mL of
buffer (10 mM Hepes pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2). The spleen was infiltrated by injection
with approximately 2 mL of Collagenase solution, the tissue was
cut into small pieces using sharp scissors, and incubated for 20
minutes at 37uC. The cell suspension and remaining tissue
fragments were gently passed through a 100 mm cell strainer (B–D)
to obtain a single cell suspension, which was washed twice by
centrifugation (500 g for 7 min at 4uC) and re-suspended in
culture medium composed of DMEM (Gibco), 5% FBS, 1 mM
Sodium pyruvate (Gibco), 1X MEM amino acids solution (Sigma),
0.02% v/v/EDTA, 10 mM HEPES buffer (Cellgro) and 100 IU/
mL Penicillin/100 mg/mL Streptomycin solution (Cellgro). The
splenocytes were counted and adjusted at concentrations from
100,000 to 500,000 cells/50 mL and used the same day for drug
screening or determination of EC50 as described below.
Primary screening of compound libraries using the ex
vivo splenic explant model
The following chemical libraries in 96-well plate format were
screened: NINDS Custom Collection II (MicroSource Discovery
Systems, Inc.), which consists of 1,040 classical therapeutic
agents, established experimental inhibitors, receptor agonist
drugs and other bioactive compounds [24,25,26]; the Pure Natural
Products library (MicroSource Discovery Systems, Inc.) a collec-
tion of 800 pure natural products and derivatives; and The
Diversity Set and Natural Products set (Developmental Thera-
peutics Program, NCI/NIH) a set of 2,195 compounds selected
from the almost 140,000 compounds based on diversity of
structure [27,28,29]. Libraries containing the compounds at
10 mM concentration in DMSO were diluted into master plates
at 200 mM concentration in DMEM. The 200 mM master plates
were further diluted by transferring an aliquot of 5 ml into a 96-
well sterile white-bottom plate (Costar) containing 45 mlo f
culture medium at 4uC. Splenocytes (100,000 in 50 mlo fc u l t u r e
medium) that had been obtained from infected hamsters as
described above were added to the assay plate for a final drug
concentration of 10 mM. The positive control (splenocytes treated
with 0.2 mM Amphotericin B) and negative controls (0.1%
DMSO vehicle) were distributed in the two outer columns (8
wells each) of each plate in alternating fashion to minimize any
edge effect [30]. After 48 hours of culture at 37uCi nah u m i d i f i e d
atmosphere and 5% CO2, the plates were centrifuged at 500 g
for 7 min, the supernatant discarded using a multi- channel
vacuum aspirator (Costar), and 20 ml of 1X cell culture lysis
reagent (Promega) was added to the cells. To complete the lysis
procedure the plates were frozen at 270uC and then thawed, and
the luciferase activity determined in a plate luminometer
following addition of 100 ml of the luciferin substrate at room
temperature (Promega). The Z score was calculated for each
compound as the mean counts of the compound tested minus the
mean counts of all compounds in the plate divided by the SD all
compounds in the plate [30]. The mean Z score for each drug
was calculated based on duplicate screenings performed in two
different experiments. A Z score of #–1.96, which corresponds to
a p value of #0.05 (95% confidence limit), was used as the
threshold to identify the hits [30]. The conditions of the screening
were optimized to obtain the best signal to noise ratio by
calculating the Z factor obtained after exposure to different drug
concentrations (10, 5, 2.5 mM). The quality of each assay was
determined by calculating the Z prime (Z’) factor [31], which
measures the discrimination between positive and negative
controls in the screen. The Z’ factor was calculated as 1 –
[(3SD positive controls +3SD negative controls)/absolute value of
(mean of the positive controls – mean of the negative controls)].
Assessment of cell toxicity (CC50) using the HepG2 cell
line
We used a cell-based assay as an alternative to animal testing to
determine the toxicity of the identified hit compounds [32]. The
cytotoxicity was evaluated in HepG2 cells (human hepatocellular
carcinoma, ATCC#HB 8065) maintained in MEM (Gibco)
supplemented with 10% FBS 1 mM sodium pyruvate (Gibco),
1X MEM aminoacids solution (Sigma), 100 IU/mL penicillin,
and 100 mg/mL streptomycin (Cellgro). Cell monolayers were
detached using 1X trypsin/EDTA (Gibco), washed and adjusted
to 500,000 cells/mL in supplemented MEM, and 50 ml of the cell
suspension were added to white-bottom 96-well plates (25,000 per
well) containing 50 ml of serial 2-fold dilutions of the test
compounds (0.1–100 mM) or the DMSO control. After 24 hours
of culture at 37uC the number of viable cells was determined by
quantification of the ATP present in the cell using the CellTiter-
Glo luminescent Cell Viability Assay (Promega). The lumines-
cence values were used to construct a curve using a linear
regression model (GraphPad Prism 5.0) and calculate the cytotoxic
concentration that killed 50% of the cells (CC50). The mean and
standard error of 3–5 different experiments were considered as the
final CC50 for the purpose of calculating the in vitro therapeutic
index (see below).
Screening of Anti-Leishmanial Compounds
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explant model
The anti-leishmanial efficacy of the compounds was determined
using the splenic explant model in a 96-well plate format. In brief,
splenocytes from infected hamsters were obtained as described
above and a suspension of 100,000–500,000 in 50 mL of culture
medium were added to white-bottom 96-well plates containing
50 ml of serial 2-fold dilutions of test compounds (0.03–20 mM) in
culture medium. Because variation in the parasite burden between
different explant cultures was expected, the concentration of cells
used in each experiment was adjusted to give approximately 100
counts by luminometry (equivalent to ,240,000 parasites). The
number of surviving parasites was determined by luminometry as
described above. Luminometry values were used to construct a
curve using a linear regression model (GraphPad Prism 5.0) and
calculate the effective concentration of the compound that killed
50% of the parasites (EC50). The mean and standard error of the
EC50 from 2–3 different experiments were considered as the final
EC50 for the purpose of ranking the compounds and calculating
the in vitro therapeutic index (see below).
Anti-leishmanial efficacy (EC50) using the in vitro infected
macrophage model
Macrophages from uninfected hamsters were obtained by
peritoneal lavage with DMEM (Gibco) and Heparin (2 units/ml;
Elkins-Sinn, Cherry Hill NJ). The cells were washed twice by
centrifugation and re-suspended in culture medium composed of
DMEM, 5% FBS, 1 mM sodium pyruvate (Gibco), 1X MEM
amino acids solution (Sigma), 0.02% v/v/EDTA and 10 mM
HEPES buffer (Cellgro). The peritoneal macrophages were
adjusted to 5610
5 cells/ml and allowed to adhere overnight at
37uC and 5% CO2 in flat bottom 96-well plates. Adherent
macrophages were infected at 1:5 ratio (cells:parasites) with
stationary phase LUC-transfected L. donovani promastigotes and
cultured at 37uC, 5% CO2, for 2 h. The extracellular parasites
were then removed by washing with warm Dulbeco’s PBS
Figure 1. Rationale for selection of the time for establishing the ex vivo splenic explant culture. Hamsters infected with 10
6 Luc-
transfected L. donovani were evaluated from 7 to 21 days post infection (n=6 per time point). (A) Spleen weight. Shown is the mean 6 standard
deviation (SD) of the spleen to body weight ratio (spleen weight divided the body weight). (B) Splenic parasite burden. The number of
amastigotes (mean 6 SD) was determined by luminometry in 500,000 splenocytes by extrapolating the counts (photons/sec) to a standard curve of
microscopy-enumerated spleen-derived amastigotes. (C) Total splenocyte number. Splenocyte number (mean 6 SD) was determined by
counting the cells by microscopy. (D) Splenocyte lymphoproliferative response. The splenocyte stimulation index (shown as the mean 6 SD)
was determined by dividing the cpm of concanavalin A-stimulated and non-stimulated splenocytes. (E) Splenic soluble collagen content. The
soluble collagen content (shown as the mean 6 SD) was determined in spleens from uninfected and infected hamsters by the Sircol assay (Biocolor).
(F) Splenic Arginase activity. Tissue arginase activity was determined by measurement of urea catalysis and is shown as the mean 6 SD. Statistical
analysis for all panels was performed by one-way analysis of variance (ANOVA).
doi:10.1371/journal.pntd.0000962.g001
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dilutions of test compounds as described above for the ex vivo
culture system. The infected macrophages were incubated for
48 hr in 5% CO2 atmosphere at 37uC. The number of surviving
parasites was determined by luminometry and the effective
concentration (EC50) calculated by linear regression (GraphPad
Prism 5.0) as described above for the ex vivo system. The mean
and standard error of the EC50 from 3 different experiments
were considered as the final EC50. The test compounds
Amphotericin B, Miltefosine, Pentamidine, Fluconazole, Anti-
mycin A, Disulfiram, Monensin A and Nortriptyline were
purchased from Sigma, and Meglumine antimoniate (Glucanti-
meH) was obtained from Aventis Pharma (Brazil, Lot: L503451).
Tilorone was obtained from Hangzhou Trylead Chemical Tech
(China). All compounds were dissolved in sterile dimethyl
sulfoxide (analytical grade, cell culture tested; Sigma) and stored
frozen at 220uC until used.
Identification of lead compounds
Hit compounds that showed a significant Z score in the ex vivo
screening but demonstrated high toxicity for the HepG2 cell line
(CC50 #10 mM) were excluded from further consideration. After
the exclusion of these toxic compounds, the in vitro therapeutic index
(IVTI), which is the ratio of the CC50 obtained in the HepG2 cell
line and the anti-leishmanial activity (EC50), was calculated for each
of the hit compounds. The resulting IVTI was used to rank the hits
and select lead compounds that had an IVTI .5.
Results
Characterization of the ex vivo explant culture
We first characterized the clinical, immunological, and
parasitological features of the infected hamster spleen early in
the course of VL (which is ultimately fatal) to identify a time point
that indicated the course of infection was transitioning toward
severe disease. At 21 days p.i. there was a dramatic increase in
spleen size (Fig. 1A), parasite burden (Fig 1B), and cellular
infiltration of the spleen (Fig 1C). The splenomegaly was related to
hypercellularity with a significant expansion of the macrophage
population (6-fold increase over uninfected spleens, p=0.016) and
B lymphocytes (Table 1). The expansion of other cell populations
that were not enumerated, such as fibroblasts, is likely to also
contribute to the splenomegaly. The transition to progressive
disease was also accompanied by loss of T cell responsiveness
(Fig 1D) and preceded by a transient decrease in the percent of
splenic CD3
+ cells and CD4
+ T cells at 14 days p.i. (Table 1). At
21 days p.i. there was also evidence of alternative macrophage
activation with a significant increase in the amount of soluble
collagen synthesis (Fig 1E) and arginase activity (Fig. 1F).
Therefore, we selected day 21 p.i. as the time point to establish
the ex vivo splenic explant culture so that the screening of small
molecules for anti-Leishmania activity would be conducted within
the milieu of the immunopathological mechanisms that lead to
progressive VL.
Optimization of the ex vivo splenic explant assay for drug
screening
For the ex vivo assay to effectively identify compounds that had
inhibitory or leishmanicidal activity it was critical that the cultured
splenocytes support the replication of the parasite in the absence of
active drug over the course of the ex vivo culture. Additionally,
since the luciferase-expressing episomal vector could be gradually
lost after hamster inoculation, we had to establish the feasibility of
quantifying parasite numbers in the ex vivo system. We found that
the luciferase activity of amastigotes strongly correlated with the
number of parasites counted by microscopy at the different times
post-infection (R
2=0.99, p,0.0001; Figure 2A). Luminometry
clearly detected amastigote viability in the ex vivo system and most
importantly demonstrated that the parasite numbers increased
over 48 hrs of culture in the absence of test compound (p,0.05, at
48 h; Fig 2B), indicating ongoing replication of the parasite. This
was confirmed by microscopic demonstration of an increase in the
percentage of infected macrophages (Fig. 2C) and an increase in
number of amastigotes per macrophage over the course of the
culture (Fig. 2D and compare Fig. 2E to 2F). Because the increase
in luminometric counts leveled off at 48 hrs of ex vivo culture the
drug screening and EC50 determinations were completed at this
time point. However, empiric testing of a subset of compounds in
72 and 96 hr splenic explant cultures showed that culturing the
explants with and without the test compound for up to 96 hrs had
no effect on the calculated EC50.
The 48 hr ex vivo culture also showed good discrimination
between drug-treated and untreated control wells. The percent
reduction in parasite burden in amphotericin B treated ex vivo
splenic explants remained relatively constant over a range of
3,000–200,000 splenocytes per well (Table 2) indicating that there
was considerable flexibility in the number of cells used for the
screening assay. For the screening of chemical libraries 100,000
splenocytes per well were used. Thus, the number of splenocytes
obtained from a single 21-day infected animal was sufficient to
screen 13 plates containing a total of 1,040 compounds. The data
in Table 2 also indicate that in situations where the number of
animals were limited, or a very large number of compounds were
going to be screened, the number of cells per well could be
reduced substantially without compromising the discrimination
Table 1. Cellular composition of the splenic explant culture
from hamsters infected with L. donovani.
Days post-infection
1
Cell type Result 0 7 14 21
Splenocytes
2 Total
2 35.0610.8 86.6656.6 119623.3
c 135.8616.0
b
CD3+ T Cells %
3 21.665.4 23.363.7 13.663.5
c 18.560.5
No.
4 7.661.9 20.263.2
d 16.164.2
d 25.160.7
d
CD4+ T Cells % 5.661.9 6.963.5 2.660.5
c 6.160.9
No. 1.860.7 6.063.0
b 3.160.5 8.361.3
a
B Lymphocytes % 14.662.0 20.365.8
c 23.764.6
b 18.161.3
No. 5.160.7 17.665.0 28.365.5
a 24.661.8
b
Macrophages % 15.464.3 17.463.0 9.562.2 23.862.6
c
No. 5.461.5 12.067.1 11.462.6 32.363.5
a
Granulocytes
5 % 3.1561.2 0.9660.4 1.4460.2 0.4660.1
1Determined in 5 uninfected hamsters and 5 infected hamsters at each time
point. The value represents the mean 6 standard deviation of the group.
2Number of total splenocytes (millions) obtained from the spleen of the
animals. Enumerated in a Neubauer chamber by light microscopy.
3Percentage of positive cells determined by flow cytometry.
4Number of cells (millions): calculated from the total number of cells multiplied
by the percentage of cells positive by flow cytometry.
5Granulocytes: percentage of granulocytes determined by Side Scatter and
Forward Scatter of cells by flow cytometry.
ap,0.001 uninfected vs. infected groups;
bp,0.01; uninfected vs. infected groups;
cp,0.05, uninfected vs. infected groups (Kruskal-Wallis test);
dp,0.001, uninfected vs. infected groups (Tukey-Kramer Multiple comparisons
test).
doi:10.1371/journal.pntd.0000962.t001
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www.plosntds.org 5 February 2011 | Volume 5 | Issue 2 | e962Figure 2. Characterization of the splenic explant cultures. (A) Representative amastigote standard curve. Correlation between the
number of L. donovani amastigotes counted by microscopy and the luciferase activity determined by luminometry. (B) Amastigote replication in
splenic explant cultures. Number of amastigotes in ex vivo explants cultures determined by luminometry and interpolation from the standard
curve over 0 to 72 hours of incubation (100,000 splenocytes per well). (C) Percent of infected macrophages in splenic ex vivo cultures.
Splenocytes harvested from infected hamsters (21 days p.i.) were plated and the proportion of infected macrophages (shown as the mean 6 SD) was
determined by microscopy at 0, 24, 48, and 72 hours of ex vivo culture. (D) Number amastigotes per 100 macrophages. Amastigotes
Screening of Anti-Leishmanial Compounds
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variation of the ex vivo splenocyte number from 100,000 to
500,000 cells per well had no effect on the calculated EC50 of a test
compound (data not shown).
To confirm the quality of the assay in discriminating active from
inactive compounds we calculated that the Z prime (Z’) factor [31]
in 3 different screening experiments using 36 different plates. The
resulting value of 0.7260.02 indicated that the assay could be
considered as optimal (optimal assay, Z factor $0.5 but #1.0)
[31]. To select the optimal drug concentration for the assays we
compared the number of hits obtained after screening 80 different
compounds at 10, 5 and 2.5 mM. Each of the concentrations gave
similar numbers of hits (data not shown), so we chose the 10 mM
concentration to be inclusive of as many hits as possible and limit
the skewing of the hit selection toward toxic compounds.
Validation and prioritization of screening hits
The initial screening using the ex vivo model showed that 239 of
4,035 compounds (5.9%) had a Z score of #–1.96 (equivalent to a
p#0.05) and could be qualified as screening ‘actives’ (Table 3). We
did not observe microscopic evidence of cell death in the splenic
explant cultures after 48 hrs of culture with the test compounds.
Flow cytometry of propidium iodide stained splenocytes cultured
with three representative test compounds (amphotericin B,
tilorone, disulfuram) confirmed no loss of splenocyte viability over
the 48 hr culture period (data not shown). To quantify cytotoxicity
of a test compound we utilized an established cell line-based assay.
We first excluded compounds that fell below an arbitrary
cytotoxicity threshold in the HepG2 cell line (CC50, 10 mM),
and after exclusion of 37 (1%) such (toxic) compounds, 202 (5%)
hits were left for further validation studies (Table 3). For each of
these hits, anti-leishmanial activity (EC50) was determined in the
ex vivo splenic explant system. Comparison of these EC50 values
with cytotoxicity (CC50) values in the HepG2 cell line allowed
determination of an in vitro therapeutic index (IVTI: CC50/EC50).
Based on a threshold IVTI score $5 [33], 84 compounds (2.1% of
the total number of molecules screened) were identified as lead
compounds (Tables 3, 4, S1). Of the 84 lead compounds, 15 (17%)
had been shown previously to have anti-leishmanial activity (Table
S2) and 69 (83%) had not been reported previously as having
activity against Leishmania (Tables 4, S1). A substantial number of
the latter, however, had been shown previously to have anti-
infective activity against other classes of pathogens, while others
were known as immune regulators, antidepressant, antipsychotics,
or had no known function (Table 5).
In general, heterocyclic compounds were most highly repre-
sented among the lead compounds, comprising 55% of the total
(Table 4). Eleven percent of the lead compounds were single-ring
heterocyclic structures, 21% had 2-ring structures, 14% were
classified as quinolines, and 7% were 3-ring phenothiazines. Ten
percent of the leads were alkaloids and 20% were hydrocarbon
structures composed of aromatics and terpenes (Tables 4, S1). The
chemical libraries screened included large numbers of known
bioactives and drugs so it was not surprising that 27 of 84 (32%)
leads had been previously used clinically. Eleven of the lead
compounds are recommended for topical use only (Table 5).
Three known anti-leishmanial drugs, fluconazole, pentamidine
and miltefosine included in the libraries surprisingly did not show
a significant Z score and were not identified as hit compounds in
the screening. To understand the reason behind this finding, we
determined the EC50 of these and other anti-leishmania drugs and
lead compounds in both the ex vivo splenic explant and in vitro
macrophage infection models (Table 6). Repeated testing of
Miltefosine from the NCI chemical library found it to be inactive,
but testing of freshly solubilized compound from a different
commercial source was found to be highly active (EC50=1mM).
Thus it would appear that the miltefosine in the NCI library had
degraded to an inactive form. Similarly, the EC50 calculated for
the amphotericin B present in the library (in DMSO vehicle) was
10.760.9 mM, whereas freshly solubilized amphotericin B deoxy-
cholate (Sigma) had an EC50 of 0.2460.02 mM. In the case of
pentamidine, the Z score of 21.87 was just outside the threshold
for statistical significance (a Z score of 21.96 is equivalent to
p=0.05) and determination of the EC50 for pentamidine revealed
that it was active in the ex vivo splenocytes system (EC50=3mM).
Fluconazole had no activity detected by either the screen or
determination of the EC50. Collectively these data indicate that the
ex vivo system is a robust approach to identification of new
compounds, but that like any screen, it is only as good as the
quality of the compounds (libraries) screened.
enumerated by direct microscopy in Giemsa stained cytospin slides (mean 6 SD in 4 different samples per time point). (E, F) Infected splenocytes
in ex vivo culture. Representative Giemsa-stained photomicrograph of splenocytes from hamsters infected with L. donovani at pre-culture (E) and
after 48h of ex vivo culture (F).
doi:10.1371/journal.pntd.0000962.g002
Table 2. Determination of splenocyte numbers required for the ex vivo assay.
No. of cells Parasite counts (photons/sec)
a Reduction in parasite burden
b
(per well) Untreated (control) Treated (AMB) (%)
3,125 0.760.0 0.160.1 83.5
6,250 1.260.2 0.260.0 86.3
12,500 2.860.9 0.460.3 86.2
25,000 5.3 60.8 0.760.0 86.4
50,000 14.260.4 2.560.5 82.3
100,000 51.0610.1 8.560.2 83.3
200,000 145.260.4 34.863.7 76.0
aParasite counts (mean 6 SD) were determined by luminometry in splenocytes isolated from hamsters at 21 days p.i. and cultured ex vivo with amphotericin B (AMB),
0.126 mg/mL or DMSO control for 48 h.
bReduction in parasite burden with reference to controls=100 - [(parasite counts in treated splenocytes/parasite counts in control wells) x 100].
doi:10.1371/journal.pntd.0000962.t002
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and in vitro macrophage infection models
To further validate the ex vivo splenic explant model for drug
screening we determined the EC50 of a subset of 10 compounds
(including 5 known anti-leishmania drugs) using both the ex vivo
and in vitro infected macrophage systems. Infected splenocytes
and in vitro infected macrophages were cultured under the same
conditions for 48 hrs in the presence or absence of serial dilutions
of test compound. We found good correlation between the two
systems (R
2=0.78; p=0.027).
Discussion
New drugs are desperately needed for the treatment of VL, and
innovative approaches are needed to identify new lead compounds
and classes of compounds that can enter the pipeline of lead
optimization and therapeutic testing. We describe here a novel
approach to drug discovery for VL. We sought to develop a model
system through which the activity of test compounds could be
determined within the physiological and immunological environ-
ment of the site of infection. Since the host immune response is
known to have profound influence on the treatment and outcome
of Leishmania infection, and VL is characterized by suppression of
cellular immune function, we felt it was critical that new
compounds be screened for activity within the immunopatholog-
ical milieu found at the site of the host-parasite interaction during
active disease. The ex vivo splenic explant culture used for the
drug screening reported here was established from L. donovani
infected hamsters that demonstrated the immunopathological
features of active VL in that 1) there was enlargement of the
spleen, 2) the splenic parasite burden was rapidly increasing, 3)
there was loss of antigen-specific T cell reactivity [34], 4) the
splenic T cell population was contracting while the B cell and
macrophage populations were expanding [35], and 5) the splenic
macrophages had acquired an alternatively activated phenotype.
Furthermore, the cultured spleen cell explants contained the full
repertoire of spleen cells and supported ongoing parasite
replication during the 48 hrs of exposure to test compound.
The novel ex vivo splenic explant model showed excellent
discrimination between active and inactive compounds in a
medium-throughput screening format. Known anti-Leishmania
drugs were readily identified upon the screening of the chemical
libraries, confirming the ability of the ex vivo model to identify
active compounds. Furthermore, the practical advantages of the ex
vivo approach presented here are numerous. The model uses a
Leishmania strain that is episomally transfected with the firefly
luciferase reporter gene, which has been successfully used by
others to quantify in vitro and in vivo infections [19,36]. The light
emission of luciferase-tranfected parasites allows one to quantify
the amastigote numbers in the samples by extrapolation to a
standard amastigote curve, making this approach readily adapt-
able to a quantitative high throughput assay. The relative high cost
of the luciferin substrate is offset by the radical decrease in labor,
high sensitivity, and reproducibility of the method. Since in the ex
vivo model the cells are harvested from infected animals and the
screening is carried out in 96-well plates, no parasitological
expertise to quantify amastigotes is necessary, and the time
consuming and potentially biased microscopy-based evaluations
that preclude automation are avoided. The fact that the luciferase-
transfected L. donovani are selected by their resistance to the
aminoglycoside G418 (Geneticin) suggests that related compounds
would not be identified in the screen, however we found that
another aminoglycoside, neomycin, was identified as a compound
with activity against the transgenic L. donovani used in the ex vivo
system. Other approaches that have used GFP-transfected
Leishmania showed that the sensitivity of measuring fluorescence
is not sufficient to enable microplate screening, and consequently a
more demanding analysis using a flow cytometer is required [37].
The requirement of animals to establish the ex vivo splenic explant
model is minimal because the cells obtained from a single infected
hamster are sufficient to screen more than 1,000 compounds.
Although axenically cultured amastigotes have been used to
screen drug candidates on a small scale [38,39] not all parasite
strains can be cultured as axenic amastigotes. It has been shown
that in vitro assays that utilize intracellular amastigotes in
macrophage cell lines correlate better with the response to
treatment in vivo compared with assays in which promastigotes
are used [40]. Screenings that involve in vitro infected macro-
phages have the technical limitation of difficulty in removal of
extracellular promastigotes, and the theoretical concern that the
non-macrophage immune regulatory cells are absent. Our results
showed that the anti-Leishmania activity of lead compounds in the
ex vivo spleen cell explants differed substantially from that found
in cultured promastigotes, and to a lesser extent from freshly
isolated tissue amastigotes. Thus, some of the lead compounds
would not have been identified if promastigotes or cell-free
Table 3. Hit and lead compounds identified from chemical libraries using the ex vivo splenic explant system.
Initial Screening Results after excluding toxic compounds
4
Compounds Z score ,21.96
6 Hits
4 Leads (IVTI.5)
7
Chemical Library No. No. %
6 No. %
6 No. %
6
NINDS Col II
1 1,040 76 7.3 65 6.3 24 2.3
NINDS NP
2 800 51 6.4 46 5.8 12 1.5
NCI
3 2,195 112 5.1 91 4.1 48 2.2
Total
5 4,035 239 5.9 202 5 84 2.1
1NINDS Col II (NINDS Collection II, MicroSource Discovery Systems).
2NINDS NP (NINDS Natural Products Collection, MicroSource Discovery Systems).
3Diversity set and Natural products set of the National Cancer Institute (NCI).
4Compounds identified by Z score, excluding the toxic compounds (CC50 ,10 mM for the HepG2 cell line).
5Total number (No.) and % of compounds excluding amphotericin B, which is considered as the reference compound.
6All percentages shown in the table refer to the total number of compounds of the initial screening. See Table S1 for compound details.
7Leads identified using the in vitro therapeutic index (IVTI) calculated of the cell toxicity (CC50) and anti-Leishmania activity (EC50)r a t i o .
doi:10.1371/journal.pntd.0000962.t003
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techniques suggests that this ex vivo screening system can be
exploited for the discovery of drugs targeting metabolic pathways
of amastigotes in the host cells and/or interacting with the
immune system. Accordingly, review of the published literature
about the mechanisms of action of the 84 lead compounds
revealed that the likely mode of action or parasite targets were the
cell membrane (21%), cell metabolism (17%), the host immune
response (13%), apoptosis (7%), and DNA interaction (6%).
The screening of compounds for anti-Leishmania activity in the
ex vivo model, coupled with screening for toxicity using the HepG2
hepatocyte cell line, enabled the selection of 84 lead compounds,
69 of which had not been identified previously to have anti-
Leishmania activity. While the use of cell lines to predict in vivo
toxicity has some limitations [41], the HepG2 cell line is
considered a good predictor of human toxicity [42,43]. Although
measurement of ATP in viable cells this method is one of the most
reliable methods to estimate cell toxicity [44] multiparametric
toxicity testing (based on features such as apoptosis markers and
membrane integrity) and other in vitro models may be desirable to
help in the assessment of hepatic cytotoxicity [45] and further lead
optimization [44]. Ultimately, the final selection of lead com-
pounds will require in vivo studies to identify dose limiting
toxicities and to evaluate whether the compound’s pharmacoki-
netic and ADME (absorption/distribution/metabolism/excretion)
properties make it suitable for use in VL. Already it is clear that
some of the lead compounds (e.g. topical and antiseptic agents) are
unlikely to be useful in treating systemic infection.
Compounds containing the heterocyclic quinoline ring system
were frequently identified in the screen as active inhibitors,
representing 14% of the lead compounds. The quinoline leads
could be further divided into several distinct classes. A number of
the leads bear obvious structural relation to antimalarial
quinolines, including several 4-aminoquinolines with basic side
chains, as well as 8-aminoquinolines and a 2-arylquinoline
derivative containing the core structure of the antimalarial drug
mefloquine. Also represented were 8-hydroxyquinoline antifungals
like clioquinol as well as more novel dimeric 2-aminoquinolines
and quinoline diones. Several of the quinoline-containing
compounds showed activity at micromolar concentrations and
low toxicity to the HepG2 cell line, suggesting that they are good
leads for optimization. Previous reports have described other
quinoline-containing compounds with anti-Leishmania activity. For
example, a 2-substitued quinoline alkaloid reduced by 79.6% the
parasite load in the liver of BALB/c mice infected with L. donovani
[46]. Sitamaquine, an 8-aminoquinoline, completed a phase II
study for treatment of VL [47], and more recently, DNDi has
incorporated synthetic 2-quinoline derivatives as part of the
strategy to develop new anti-Leishmania drugs (http://www.dndi.
org/newsletters/n18/edito.php). The quinoline ring system is
common in known drugs and other bioactive molecules and such
compounds can exhibit distinct bioactivities depending on their
specific structures. Previously, quinoline derivatives have been
reported to affect electron transport and generate lethal oxidative
radicals against Leishmania, and also to inhibit cysteine proteases
[48], a gene family important for Leishmania virulence [49]. Other
quinoline derivatives have also been shown to alter the vesicle
trafficking and endocytosis in Plamodium falciparum [50]. Our
results, together with these prior observations, suggest the likely
possibility that multiple distinct bioactivities are represented
among the quinoline leads identified here and that multiple
pharmacologically orthogonal candidates might be selected for
further lead optimization studies.
Alkaloids also represented an important fraction of the lead
compounds (10%) identified in the ex vivo screening. This parallels
the observation that alkaloids derived from natural products have
been found to be active against Leishmania species (reviewed by [51]).
Table 4. Lead compounds newly identified or previously
known to have anti-leishmanial activity.
New Known Total
Compound
1 No. % No. % No. %
Heterocyclic compounds
1-ring
F u r a n s 341745
Pyridines 1 1 0 0 1 1
P i p e r i d i n e s 110011
Pyrans 0 0 3 20 3 4
5642 7 91 1
2-ring
Isoquinolines 2 3 0 0 2 2
Quinolines 12 17 0 0 12 14
P u r i n e s 110011
Benzopyrans 2 3 0 0 2 2
Bicyclocomp. 1 1 0 0 1 1
18 26 0 0 18 21
3-ring
Phenothiazines 5 7 1 7 6 7
Acridines 1 1 0 0 1 1
Xanthenes 3 4 0 0 3 4
Phenanthridines 0 0 1 7 1 1
9 13 2 13 11 13
Alkaloids 8 12 0 0 8 10
Hydrocarbons
Aromatics 8 12 1 7 9 11
Terpenes 6 9 1 7 7 8
Acyclic 1 1 0 0 1 1
15 22 2 13 17 20
Polycyclic compounds
Macrocyclic 1 1 1 7 2 2
Steroids 1 1 2 13 3 4
2332 0 56
Amines
Ethylamines 1 11 0 0 1 1
Q.
ammonium
290022
Polyamines 1 1 0 0 1 1
460045
Lactones 1 1 2 13 3 4
Onium comp. 2 3 1 7 3 4
S u l f u r c o m p . 230022
2 O t h e r s 341745
Total 69 82 15 18 84 100
1Chemical name according the MeSH Chemical Class Browser (Wolfram
Demonstrations project), National Library of Medicine, National Institutes of
Health, United States 2010.
2Others: Amidines, Phenols, Carboxilic Acids, Organometallic compounds.
doi:10.1371/journal.pntd.0000962.t004
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a mode of action for a number of compounds (ionophores,
quaternary ammonium salts and tricyclic anti-depressants [52])
that were identified as leads in our screen (Tables 4, S1). In
addition to a possible direct effect on the parasite membrane these
inhibitors have the potential to affect the membrane integrity of
the parasitophorous vacuole in which Leishmania resides, and
perturb the capability to regulate the intraphagosomal trafficking
of essential substrates for parasite survival [53]. Specific inhibition
of biosynthesis of phosphatidylcholine has been proposed for some
quaternary ammonium salts active against L. major promastigotes
and L. braziliensis [54]. One of the leads identified here,
cetrimonium bromide, is a cationic surfactant that closely
resembles the structure of hexadecylphosphocholine (miltefosine),
a drug in current use for VL. It has also been shown to inhibit
choline kinase that regulates the biosynthesis of the most abundant
phospholipid (phosphatidylcholine) in Plasmodium falciparum [55].
Because these lead compounds are recommended only for topical
and not systemic administration they will not be drug candidates
for VL, but identification of their molecular targets could facilitate
new screening campaigns that could identify lead compounds
more suitable for systemic use.
Phenothiazine compounds related to the tricyclic antidepres-
sants constituted 7% of the leads, but their favorable IVTI was
primarily a result of their low toxicity, rather than their good anti-
Leishmania activity (EC50 1162.7 mM). This class of drugs was
identified as having in vitro anti-Leishmania activity 30 years ago,
but the absence in the literature of any in vivo therapeutic data
would suggest that may not have good clinical efficacy. Other
phenothiazine compounds are potent inhibitors of parasite
trypanothione reductase, a key enzyme involved in many redox
defenses of Leishmania. However, no correlation between anti-
leishmanial efficacy and the potency of several trypanothione
reductase inhibitors was found [56].
A broad range of biological effects have been recognized for the
hydrocarbon terpenes, which represented 8% of the lead
compounds. After alkaloids, natural product triterpenes are the
inhibitors found most frequently as having activity against
Leishmania spp. [51]. The terpenoids of the plant family Asteraceae
parthenolide have been shown to inhibit amastigotes and promas-
tigotes of L. amazonensis [57]. An analog of Harmine, a beta-
carboline amine alkaloid identified in our screening, reduced the
spleen parasite load by 40–80% in hamsters through necrosis and
non-specific parasite membrane damage [58]. However, the
selection of inhibitors targeting parasite specific metabolic
pathways without altering the host’s cell would be more desirable.
Table 5. Therapeutic category of anti-leishmanial
compounds identified in the ex vivo splenic explant system.
Anti-protozoa Anti-bacterial Anti-helmintic
Elipticine Nonactin Pararosaniline Pamoate
Nigericin Aklavine Hydrochloride Naphthofuran
d
Cepharanthine Nigericin Cetrimonium Bromide
Disulfiram Naphthofuran
d Disulfiram
Tilorone Streptovitacin A
3-phenanthren
a 5-methyl-8-quinolinol
c Anti-fungal
Benzalkonium
Chloride
Securinine Pararosaniline Pamoate
Physalin Cepharanthine Naphthofuran
d
Chlorhexidine Parthenicin Cetrimonium Bromide
Cloxyquin Disulfiram Disulfiram
Tetrandrine Salinomycin, Sodium Acrisorcin
Clioquinol Rubescensin A Benzalkonium Chloride
Hexachlorophene 7-hydroxychlorpromazine Clioquinol
Lasalocid Sodium Lasalocid Sodium Hexachlorophene
Lasalocid Sodium
Anti-neoplastic Topical/Antiseptics Antimycin A
Aklavine
Hydrochloride
5-methyl-8-quinolinol
c 5-methyl-8-quinolinol
c
Thaspine, Acetate Cetrimonium bromide
Ellipticine Benzalkonium chloride Immune response regulator
NSC 134754 Chlorhexidine n6-Isopentenyladenine
Streptovitacin A Clioquinol Spermidine
Trihydrochloride
Cepharanthine Hexachlorophene NSC 13480
Benzethonium
Chloride
Cetylpyridinium Chloride 6,49-Dimethoxyflavone
Rubescensin A NSC 371488
10-Methyl-9-
anthracenyl
f
Anti-viral Sumilit bbm
Tilorone Nigericin Securinine
Crassin Cepharanthine Cepharanthine
Tetrandrine Trimethoxychalcone
g
NSC 305819 Tilorone Anti-obesity/Anti-psychotics
NSC 371488 Benzalkonium Chloride 1h-benz[de]isoquinoline
b
Clioquinol Crassin Acetate Nortriptyline Hydrochloride
Fastigilin B Disulfiram
Thioxanthen-9
e Undefined
h Orlistat
Crassin acetate Thiomethylpromazine
6,49-
dimethoxyflavone
Chlorpromazine
7-hydroxychlorpromazine
Maprotiline hydrochloride
a3-phenanthrenemethanol, alpha.-[(diethylamino)methyl]-,hydrochloride.
b1h-benz[de]isoquinoline-1,3(2 h)- dione, 5-amino-2-[2-(diethylamino)ethyl]-
c7-(2-(6-ethoxy-1-methyl-1lambda(5)-quinolin-2-yl)vinyl)-5-methyl-8-quinolinol.
dnaphtho(2,1-b)furan, 4 methoxy-2 -nitro-
ethioxanthen-9-one, 4-(hydroxymethyl)-1-[(2-piperidinoethyl)amino.
f10-Methyl-9-anthracenyl) methyl carbamimidothioic acid ester hydrochloride.
g29,4-dihydroxy-3,49,69 Trimethoxychalcone.
hUndefined activity: pyrimido[4,5-b]quinoline-2,4(3 h,10 h)-dione, 5-[[3-
(dimethylamino)propyl]amino]- 3,10-dimethyl-,monohydrochloride]-; 17-(1-((2-
(dimethylamino)ethyl)amino)ethyl) estra-1,3,5(10)-trien-3-ol; N1-(7-chloro-
1,2,3,4-tetrahydro-9-acridinyl)-N3,N3-dimethyl-1,3-propanediamine; 2-[(2E)-2-
hydroxyimino-4,6,6-trimethyl-1-cyclohex-3-enyl]-4,6,6-trimethyl-cyclohex-3-en-
1-ol; 3-(12H-benzo[a]phenothiazin-12-yl)-N,N-dimethyl-1-propanamine; 5-
Phenyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-5-ol; 7-chloro-N-(4-(1-
piperidinyl)cyclohexyl)-4-quinolinamine; 2-(3-dimethylaminopropylamino)-1,4-
dihydroxy-anthracene-9,10-dione; 17-(Bis(2-hydroxyethyl)amino)androst- 5-en-
3-ol; N1-7-chloro-4-quinolinyl)-N2-cyclohexyl-1,2-ethanediamine; 6-methoxy-
N-[2-(2-piperidyl)ethyl]quinolin-8-amine.
doi:10.1371/journal.pntd.0000962.t005
Table 5. Cont.
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comprised of the full repertoire of host cells including chronically
infected macrophages and fibroblasts, enabled the identification of
small molecules that have anti-Leishmania activity within the
immunopathological milieu that closely resembles the in vivo
features of progressive VL. The inclusion of the complex biological
interactions between the parasite and host within the test system
may also favor the identification of lead compounds that act at
multiple targets [59]. The standardized approach presented here
identified a number of compounds that had good potency,
including some that are currently in clinical use for other
indications. Further study in animal infection models seems a
prudent next step for those agents already used systemically.
Among the other lead compounds identified in this work are
several interesting chemotypes (e.g. quinolines) that are good
candidates for a lead optimization. The identification of highly
active anti-leishmanial compounds in this ex vivo model of VL
could contribute greatly to new drug discovery for this serious and
neglected disease.
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Table 6. Comparative anti-Leishmania donovani activity of lead compounds in the ex vivo splenic explant model and in vitro
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Ex vivo model Peritoneal Macrophages
Compound EC50 (mM; mean±SE)
1 EC50 (mM; mean±SE)
1
Amphotericin B 0.0960.03 0.1160.01
Miltefosine 1.0260.08 2.2860.21
Pentamidine 3.0260.34 0.8960.37
Fluconazole .250 .250
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1Effective concentration of the compound that killed 50% of the parasites (EC50). Determined at 48 h of culture by luminometry.
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